Navigation Links
Fuisz Pharma LLC Announces Acquisition of Dysmenorrhea Treatment
Date:4/18/2011

MIAMI, April 18, 2011 /PRNewswire/ -- Fuisz Pharma announced that it has secured an exclusive license for a vaginal treatment of dysmenorrhea. The exclusive license covers existing clinical work whereby a medicated tampon was used to deliver keterolac and it includes two issued United States patents.

Joseph Fuisz, Managing Partner of Fuisz Pharma, stated, "We are pleased to announce this acquisition, having had a long standing interest in vaginal drug delivery, and in particular in the exciting patent portfolio originated by UMD prior to its acquisition by Femina Pharma."

"We look forward to seeking a marketing partner for this treatment.  The existing oral methods are not satisfactory and we believe that the market is finally taking notice of consumer acceptance of vaginal delivery."

The Fuiszes currently have a personal, majority position in Femina Pharma.  Prior to Femina's acquisition of UMD's assets, they had concluded an earlier license of UMD's technology.

Joseph Fuisz continued: "We see an exciting future for Femina's vaginal drug delivery portfolio, through the licensed technology as well as through recent allowances in the anti viral area in which vaginal delivery has interesting applications.  Vaginal delivery of anti virals is particularly exciting in view of limited absorption of many of these compounds when administered orally."

About Fuisz Pharma:

Fuisz Pharma (www.fuisz.com) is a private pharmaceutical technology company originated by the Fuiszes. The Fuiszes have made substantial contributions in drug delivery including orally dissolving tablets and novel particle coating systems at Fuisz Technologies; inventing and developing thin film drug delivery technologies at Kosmos Pharma and MonoSol Rx, as well as independently developing extruded sheet technology, and have extensive experience working with big and specialty pharma.


'/>"/>
SOURCE Fuisz Pharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
2. Fuisz Pharma Announces Novel Anti Abuse System for Opiates
3. FUISZ Announces Advances in Devices and Solid Dosage Form
4. Fuisz Pharma Announces Acquisition of Key Anti Opiate Abuse Patent to Complement its Anti Opiate Abuse Platform
5. Fuisz Announces Issuance of Patent for the New Generation of Glucose and Other Analyte Analyzers
6. Fuisz Pharma Releases Clinical Photos of Its Opioid Abuse Detection System
7. Fuisz Pharma LLC Develops a New Generation of Oral Solid Dosage Form Shapes That Facilitate Swallowing and Esophageal Transit
8. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 12, 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ ... Company will ring the Nasdaq Closing Bell at the ... at 4:00 p.m. ET on Tuesday, February ... Adrian Adams , will perform the honorary ... 4:00 p.m. ET.  A live webcast will be available ...
(Date:2/12/2016)... , 12 februari 2016 AAIPharma ... toonaangevende leverancier van productie en ontwikkeling op ... kondigt vandaag een uitbreiding aan van steriele ... locatie in Charleston, SC ... tot meerdere recente investeringen. http://photos.prnewswire.com/prnh/20150806/256637LOGO ...
(Date:2/12/2016)... , Ungarn, February 12, 2016 ... das sich auf den ungedeckten medizinischen Bedarf ... positive Ergebnisse seines klinischen Forschungsprogramms bekannt. Das ... beschäftigt, ergab Verbesserungen ihrer respiratorischen Funktionen und ... ltd , ein Medizintechnikunternehmen, das sich auf ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... February 13, 2016 , ... Christie Medical ... in-kind gift of a VeinViewer® Vision vein finder for the nursing ... start an IV and draw blood, combining technology with traditional technique. , “VeinViewer ...
(Date:2/12/2016)... ... 12, 2016 , ... According to an article published February 4th ... significant portion of hernia repairs throughout the United States. Commenting on this article, Beverly ... that this trend has not only been expected, but it seems to be a ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Lymphoma ... innovative lymphoma research and serving the lymphoma community through a comprehensive series of ... South Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on Monday, February ...
(Date:2/12/2016)... ... February 12, 2016 , ... As a former television executive, owner Tal Rabinowitz ... no time to decompress, Rabinowitz found herself drawn to a casual meditation class while ... on her life, implementing a 20-minute-per-day meditation practice with her team. After her tenure ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... Service (WaaS), today announced the integration of Clarity Intelligence Platform (CIP) into Cielo®, ... to offer real-time business intelligence (BI) to their small and medium business (SMB) ...
Breaking Medicine News(10 mins):